DISPOSITION OF DRUGS IN CYSTIC-FIBROSIS .3. ACETAMINOPHEN

被引:27
作者
HUTABARAT, RM
UNADKAT, JD
KUSHMERICK, P
AITKEN, ML
SLATTERY, JT
SMITH, AL
机构
[1] UNIV WASHINGTON,SCH PHARM,DEPT PHARMACEUT,DIV PULM & CRIT CARE MED,BG-20,SEATTLE,WA 98195
[2] UNIV WASHINGTON,DEPT PEDIAT,DIV PULM & CRIT CARE MED,SEATTLE,WA 98195
[3] UNIV WASHINGTON,DEPT MED,DIV PULM & CRIT CARE MED,SEATTLE,WA 98195
[4] CHILDRENS HOSP & MED CTR,SEATTLE,WA
关键词
D O I
10.1038/clpt.1991.209
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The disposition of acetaminophen after oral administration was investigated in adults with cystic fibrosis (n = 5) and in age-matched healthy control subjects (n = 5). The total plasma clearance of acetaminophen was found to be greater (p < 0.025) in subjects with cystic fibrosis (0.362 +/- 0.081 L/hr/kg) than in control subjects (0.247 +/- 0.022 L/hr/kg). This difference in clearance was found to be primarily attributable to a greater metabolic clearance of acetaminophen to acetaminophen sulfate (0.080 +/- 0.023 L/hr/kg for subjects with cystic fibrosis and 0.045 +/- 0.008 L/hr/kg for control subjects; p < 0.05) and to a greater metabolic clearance of acetaminophen to acetaminophen glucuronide (0.189 +/- 0.051 L/hr/kg for subjects with cystic fibrosis and 0.114 +/- 0.017 L/hr/kg for control subjects; p < 0.05) in persons with cystic fibrosis. Of the mechanisms that may be responsible for these differences, the most likely is enhanced activity (in subjects with cystic fibrosis) of the transferases that mediate the metabolism of acetaminophen to acetaminophen sulfate and acetaminophen glucuronide, respectively.
引用
收藏
页码:695 / 701
页数:7
相关论文
共 27 条
[1]  
BIGELOW C, 1984, THESIS U WASHINGTON
[2]   UDP-GLUCURONOSYLTRANSFERASE ACTIVITIES - GUIDELINES FOR CONSISTENT INTERIM TERMINOLOGY AND ASSAY CONDITIONS [J].
BOCK, KW ;
BURCHELL, B ;
DUTTON, GJ ;
HANNINEN, O ;
MULDER, GJ ;
OWENS, IS ;
SIEST, G ;
TEPHLY, TR .
BIOCHEMICAL PHARMACOLOGY, 1983, 32 (06) :953-955
[3]   HUMAN-LIVER PHENOL SULFOTRANSFERASE - ASSAY CONDITIONS, BIOCHEMICAL-PROPERTIES AND PARTIAL-PURIFICATION OF ISOZYMES OF THE THERMOSTABLE FORM [J].
CAMPBELL, NRC ;
VANLOON, JA ;
WEINSHILBOUM, RM .
BIOCHEMICAL PHARMACOLOGY, 1987, 36 (09) :1435-1446
[4]   INCREASED SULFATION OF GLYCOCONJUGATES BY CULTURED NASAL EPITHELIAL-CELLS FROM PATIENTS WITH CYSTIC-FIBROSIS [J].
CHENG, PW ;
BOAT, TF ;
CRANFILL, K ;
YANKASKAS, JR ;
BOUCHER, RC .
JOURNAL OF CLINICAL INVESTIGATION, 1989, 84 (01) :68-72
[5]  
CHUNGSOOK K, 1985, THESIS U WASHINGTON
[6]   ANTIBIOTIC PHARMACOKINETICS IN CYSTIC-FIBROSIS - DIFFERENCES AND CLINICAL-SIGNIFICANCE [J].
DEGROOT, R ;
SMITH, AL .
CLINICAL PHARMACOKINETICS, 1987, 13 (04) :228-253
[7]   PHARMACOKINETICS OF TICARCILLIN IN PATIENTS WITH CYSTIC-FIBROSIS - A CONTROLLED PROSPECTIVE-STUDY [J].
DEGROOT, R ;
HACK, BD ;
WEBER, A ;
CHAFFIN, D ;
RAMSEY, B ;
SMITH, AL .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1990, 47 (01) :73-78
[8]  
Fairbrother JE., 1974, ANAL PROFILES DRUG S, P1
[9]   PURIFICATION AND CHARACTERIZATION OF HUMAN LIVER PHENOL-SULFATING PHENOL SULFOTRANSFERASE [J].
FALANY, CN ;
VAZQUEZ, ME ;
HEROUX, JA ;
ROTH, JA .
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1990, 278 (02) :312-318
[10]  
Gibaldi M., 1982, PHARMACOKINETICS, V2nd ed., P409